Effect of DPP4 Inhibition on Growth Hormone Secretion
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This study tests the following hypotheses:
Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the
currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone
(GH) secretion in healthy lean adults by decreasing the degradation of growth hormone
releasing hormone (GHRH).
Aim 2: Test the hypothesis that decreased degradation of GHRH during acute DPP4 inhibition
will result in an increase in endothelium-dependent vasodilation mediated by GH and
independent from GLP1 (glucagon like peptide-1) in healthy lean adults.
This study promises to provide novel data regarding how this increasingly used class of
anti-diabetic drugs affects the pituitary GH axis and could affect blood vessel relaxation.
Growth hormone levels are low in the setting of obesity and pre-diabetes. A further study may
evaluate the effect of chronic DPP4 inhibitor therapy in a population of patients with
obesity and pre-diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)